TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03068754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Repository corticotropin for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Repository corticotropin for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Repository corticotropin for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for subcutaneous injection
Study: NCT04099121

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound Imaging
Description: 3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
Study: NCT04567394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Network Counseling-txt
Description: 4-week text counseling program
Study: NCT04588116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies Empowering activities in Everyday life (SEE 1.0)
Description: The patients are provided a person-centered activity-based intervention on the web aiming at facilitating the level of engagement in a variety of activities, at different places in society, together with other people to support an active life. In the long-term, the change to an active life will be reflected in a healthy and balanced pattern of activities.~The program provide the patients with tools to see their activities in everyday life in a new light and, also, tools to identify activity-based strategies that can empower them to take an active role to prevent and overcome challenging situations in everyday life.
Study: NCT02118272

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica KR
Study: NCT01611194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 1.5 atms
Description: The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham control 1.2 atms
Description: The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
Study: NCT01361178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SQ IVIG
Description: Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
Study: NCT00767819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
Study: NCT02152319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KHV reporting
Description: Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Subjects will receive the same disease management as if they were not participating in this study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Subjects will receive the same disease management as if they were not participating in this study.
Study: NCT02602418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive WM CogMed Training
Description: 12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects.

Intervention type: OTHER
Group type: OTHER
Intervention: Adaptive WM CogMed Training
Description: 12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonadaptive WM CogMed Training
Description: The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions).

Intervention type: OTHER
Group type: OTHER
Intervention: Nonadaptive WM CogMed Training
Description: The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions).
Study: NCT03225703

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hopping
Description: A unilateral, hopping based exercise programme lasting six months.
Study: NCT03944291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Nerve Block
Description: Pudendal Nerve Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Nerve Block
Description: Pudendal Nerve Block
Study: NCT04535921

Intervention type: OTHER
Intervention: FCR7 questionnaire
Description: A 7 item questionnaire about fear of cancer recurrence
Study: NCT00716846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 10mg, 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: 2mg
Study: NCT02850380

Intervention type: OTHER
Group type: OTHER
Intervention: FLIP SWITCHES DOWN IN WEIGHTLESSNESS
Description: The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below).
Study: NCT02119663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets to be administered by mouth twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5 mg matching placebo tablets to be administered by mouth twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 150 mg or 500 mg tablets to be administered by mouth twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
Study: NCT04535921

Intervention type: OTHER
Intervention: FCR7 questionnaire
Description: A 7 item questionnaire about fear of cancer recurrence

Intervention type: OTHER
Intervention: FCR7 questionnaire
Description: A 7 item questionnaire about fear of cancer recurrence

Intervention type: OTHER
Intervention: FCR7 questionnaire
Description: A 7 item questionnaire about fear of cancer recurrence
Study: NCT04542252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB V-1901
Description: SyB V-1901 10 mg via IV infusion for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB V-1901
Description: SyB V-1901 10 mg via IV infusion for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 200 mg Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 200 mg Capsule
Study: NCT02258204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01301222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj. Octreotide
Description: 100 mcg subcutaneously for 5 days
Study: NCT02485028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 50mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 50mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 50mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 50mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 50mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirodenafil 50mg tablet
Study: NCT00895791

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AXXESS Biolimus A9-eluting bifurcation stent
Description: implantation of stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: culotte stenting (Xience V)
Description: implantation of stent
Study: NCT00329433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desirudin (Iprivask™)
Description: Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
Study: NCT03398889

Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal microbiome
Description: amplification and sequencing of 16S rRNA gene variable regions in stool samples
Study: NCT02500732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: 40mg PO the night before and the morning of the study tilt table test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo capsule designed to blind the atomoxetine intervention
Study: NCT00429026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 intravenous (IV) daily for 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 intravenous (IV) daily for 5 Days
Study: NCT00262899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study: NCT02863328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once-daily.
Study: NCT00429026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 IV Daily for 2 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV Daily for 2 Days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
Study: NCT00281736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV
Study: NCT02863328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: Oral administration once-daily.
Study: NCT00699660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPS/WHODAS
Description: CAPS/WHODAS structured clinical PTSD interview

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nonstructured Interview
Description: Usual PTSD clinical PTSD interview, not CAPS or SCID
Study: NCT01304537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin 40mg (AAT, Glassia®)
Description: Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin 60mg (AAT, Glassia®)
Description: Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
Study: NCT03159728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educative intervention:
Description: * In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~* In Module I: to strengthen the knowledge of the situation and the people involved in care.~* In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~* In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self.
Study: NCT02188615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
Description: Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: only Radical Chemoradiotherapy
Study: NCT02174952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help version of the New Forest Parenting Programme
Study: NCT03981523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: 50 mg and 100 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: 50 mg and 100 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: 50 mg and 100 mg tablet taken orally
Study: NCT01304537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin 80mg (AAT, Glassia®)
Description: Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
Study: NCT01679873

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assess one type of abstract in the randomized arm
Description: Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assess one type of abstract in the randomized arm
Description: Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
Study: NCT03981523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox
Description: 120 mg tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox
Description: 120 mg tablet taken orally
Study: NCT03619044

Intervention type: OTHER
Group type: OTHER
Intervention: 2 FES-PET Imaging will be performed:
Description: * before treatment initiation~* before treatment cycle 3 initiation
Study: NCT02188615

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mckeown MIE
Description: only Mckeown MIE using thoracoscopy and laparoscopy
Study: NCT03981523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox
Description: 120 mg tablet taken orally
Study: NCT01289964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Cupping or fire cupping
Description: 5 dry cupping treatments, application twice a week, non standardised procedure
Study: NCT02209376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-EGFRvIII T cells
Study: NCT04614142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Description: The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
Study: NCT04478552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Description: It involves injecting local anaesthetic agent (levobupivacaine) into the fascia iliaca compartment of the patient, infiltrating three major nerves that supply the medial, anterior and lateral thigh, namely the femoral and lateral femoral cutaneous nerves. This procedure can be done with anatomical landmark approach or under image guidance.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: same volume of normal saline, instead of levobupivacaine, will injected using the same technique.
Study: NCT04184271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride
Description: Topical application of SDF to teeth
Study: NCT00711022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™, all dimensions.
Study: NCT03029156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aeroneb nebulizer
Description: The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Small volume jet nebulizer
Description: The bronchodilators will be administered via small volume jet nebulizer
Study: NCT04004754

Intervention type: DRUG
Intervention: Miltefosine (administration is not part of study procedures)
Description: Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
Study: NCT02506101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narrow-band ultraviolet B phototherapy
Description: There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
Study: NCT00157157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
Description: Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion.
Study: NCT03861884

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assessments
Description: Cognitive assessment and MRI at 3T and/or 7T
Study: NCT01679873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assess one type of abstract in the randomized arm
Description: Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
Study: NCT04233450

Intervention type: OTHER
Intervention: BodyBabe questionnaire
Description: assessment of young mothers' perceptions using self-questionnaires
Study: NCT02970578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printed module
Description: The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
Study: NCT01128439

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03503500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laid-back breastfeeding
Description: At randomization the Italian version of the video Biological nurturing, which provides detailed information on LB BF, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, adequately trained staff will support women to breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves. In the maternity ward a daily supervision by an external expert on LB BF will be provided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: 2. the standard care in use at the Institute (WHO/UNICEF 20-hours course) (control group). At randomization, the Italian version of the video Breast is best (Allattare informati), which provides detailed information on standard support to breastfeeding, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, the staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast
Study: NCT01605084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
Study: NCT01939587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680 20 mg